A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid
| Autor: | Sheryl A. Dorsey, Gennethel Pennick, Deanna A. Sutton, Thomas F. Patterson, Wieslaw B. Furmaga, James S. Lewis, Nathan P. Wiederhold, Annette W. Fothergill |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Posaconazole
Antifungal Agents Itraconazole Triazole Antifungal drug Pharmacology Clinical Therapeutics High-performance liquid chromatography chemistry.chemical_compound medicine Bioassay Humans Pharmacology (medical) chemistry.chemical_classification Voriconazole business.industry Triazoles Infectious Diseases Pyrimidines chemistry Azole business medicine.drug |
| Zdroj: | Antimicrobial agents and chemotherapy. 58(1) |
| ISSN: | 1098-6596 |
| Popis: | Interest in antifungal therapeutic-drug monitoring has increased due to studies demonstrating associations between concentrations and outcomes. We reviewed the antifungal drug concentration database at our institution to gain a better understanding of achievable triazole drug levels. Antifungal concentrations were measured by high-performance liquid chromatography (HPLC), ultraperformance liquid chromatography and single-quadrupole mass spectrometry (UPLC/MS), or a bioassay. For this study, only confirmed human bloodstream (serum or plasma) and cerebral spinal fluid (CSF) concentrations of voriconazole, posaconazole, and itraconazole were analyzed. The largest numbers of bloodstream and CSF samples were found for voriconazole (14,370 and 173, respectively). Voriconazole bloodstream concentrations within the range of 1 to 5.5 μg/ml represented 50.6% of samples. Levels below the lower limit of quantification (0.2 μg/ml) were observed in 14.6% of samples, and 10.4% of samples had levels of ≥5.5 μg/ml. CSF voriconazole levels ranged from undetectable to 15.3 μg/ml and were |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|